Oxford Biomedica plc, announces that it has signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. a Philadelphia, USA-based clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The LSA grants Cabaletta Bio a non-exclusive license to Oxford Biomedica"™s LentiVector® platform for its application in Cabaletta Bio"™s leading Chimeric AutoAntibody Receptor (CAAR) T programme, DSG3-CAART (targeting DSG3), and puts in place a multi-year Supply Agreement. The financial arrangements of this LSA are in line with comparable deals the Group has previously secured.

Cabaletta Bio"™s DSG3-CAART product candidate utilises Cabaletta"™s CAAR T approach, in which the patient"™s own T cells are genetically engineered to express the target autoantigen and direct them to recognise and eliminate the pathogenic B cells. DSG3-CAART is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris (mPV), a prototypical B cell-mediated autoimmune disease. The LSA also allows for the parties to initiate additional projects in the future.